JMP Securities has reiterated its "Market Outperform" rating for ACADIA Pharmaceuticals (ACAD, Financial), maintaining its previous price target of $37.00 USD. The decision, announced by analyst Jason Butler on June 26, 2025, indicates continued confidence in the company's stock performance.
ACADIA Pharmaceuticals (ACAD, Financial) has been consistently evaluated by JMP Securities, with no change in the price target from the prior assessment. This steady projection underscores a stable outlook for the company's market position.
Investors should note that this reaffirmation of the "Market Outperform" rating reflects the analyst's positive sentiment towards ACADIA Pharmaceuticals' (ACAD, Financial) future potential. The unchanged price target signifies a sustained belief in the stock's ability to reach or exceed the $37.00 USD mark in the foreseeable future.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 18 analysts, the average target price for ACADIA Pharmaceuticals Inc (ACAD, Financial) is $27.67 with a high estimate of $38.00 and a low estimate of $15.00. The average target implies an upside of 22.83% from the current price of $22.53. More detailed estimate data can be found on the ACADIA Pharmaceuticals Inc (ACAD) Forecast page.
Based on the consensus recommendation from 20 brokerage firms, ACADIA Pharmaceuticals Inc's (ACAD, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for ACADIA Pharmaceuticals Inc (ACAD, Financial) in one year is $34.43, suggesting a upside of 52.85% from the current price of $22.525. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the ACADIA Pharmaceuticals Inc (ACAD) Summary page.
